close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Inozyme Pharma, Inc. - Common Stock (NQ:INZY)

4.000 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Inozyme Pharma, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference
- Douglas A. Treco, Ph.D., CEO and Chairman, to participate in panel discussion - 
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma to Participate in Upcoming Investor Conferences
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England’s Generation Study of Rare Conditions
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma to Host Virtual Investor and Analyst Event on Sep. 26, 2023
Company to share interim data updates from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) 
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma, Inc. Announces Closing of Public Offering of Common Stock
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma, Inc. Announces Pricing of Public Offering of Common Stock
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma, Inc. Announces Proposed Offering of Common Stock
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma to Provide ENPP1 Deficiency Program Update on July 26, 2023
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma to Present at the Jefferies Healthcare Conference
From Inozyme Pharma Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today